NASDAQ:DRMA

Dermata Therapeutics Q3 2025 Earnings Results & Report

Dermata Therapeutics logo
$0.57 -0.03 (-4.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+1.56%)
As of 11/17/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dermata Therapeutics missed analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$1.65 versus the -$1.59 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Dermata Therapeutics EPS Results

Actual EPS
-$1.65
Consensus EPS
-$1.59
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Dermata Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Dermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Dermata Therapeutics Q3 2025 Earnings FAQ

Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$1.65 per share for Q3 2025, missing the consensus estimate of -$1.59. The report was announced on Friday, November 14, 2025.

Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page.

Dermata Therapeutics Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on Wednesday
See More Dermata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email.

About Dermata Therapeutics

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies.

Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.

View Dermata Therapeutics Profile